Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
chloroprocaine hydrochloride
- Development stage
- Phase 4
- Lead developer
- Sintetica
- Modality
- Small Molecules
- Administration
- Ophthalmic, Topical
01
Overview
AMP-100, now known by the brand name Iheezo, is a preservative-free, topical ophthalmic gel formulation of chloroprocaine hydrochloride, an ester-type local anesthetic. Developed by Sintetica and licensed to Harrow Health for the U.S. and Canadian markets, it was approved by the FDA in September 2022 for ocular surface anesthesia. The drug is intended for use during various ophthalmic procedures, such as cataract surgery and intravitreal injections, providing rapid-onset anesthesia. Its approval marked the first time chloroprocaine was authorized for ophthalmic use in the United States, offering a clinical alternative to traditional topical anesthetics like lidocaine or tetracaine.
- Brand names
- Iheezo
- Other names
- chloroprocaine
Beyond the preview
Go deeper on chloroprocaine hydrochloride.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on chloroprocaine hydrochloride.